Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:
   

Zoetis Starts New Site Construction in Suzhou

publication date: Apr 29, 2018

Zoetis Inc., a multi-national animal health company, started constructing its 43,000 square meters of new facility in Suzhou. The new site will be used for vaccine manufacturing operations and laboratory space, specifically for manufacturing of viral and bacterial vaccines, including pilot scale manufacturing for the development of new vaccine products. Zoetis expects to complete construction and Good Manufacturing Practices certification by the Chinese Ministry of Agriculture by 2021. The new facility will create 100 new R&D manufacturing positions. More details....

Stock Symbol: (NYSE: ZTS)

Share this with colleagues:  



Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes


Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China